ROCKVILLE, Md., Feb. 21 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the 7th Annual North America Forum for Investing and Partnering in Biotech, to be held at The Fairmont Copley Plaza, Boston, Massachusetts on February 25-26, 2008. Mr. Burns' presentation is scheduled for Monday, February 25, 2008 at 10:45 a.m. (local time).
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) Mr. Burns' live presentation will not be web cast, but will be available through the Company's web site at http://www.entremed.com/ .
About EntreMed EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. Panzem(R) (2-methoxyestradiol) NCD is also in multiple Phase 2 studies in oncology patients. Additionally, ENMD-1198, a novel anticancer drug, is in Phase 1 studies in advanced cancers. The Company has approved IND applications for Panzem(R) in rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora- angiogenesis inhibitor, for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com/ and in various filings with the Securities and Exchange Commission.
CONTACT:
Ginny Dunn
Associate Director
Corporate Communications &
Investor Relations
EntreMed, Inc. 240-864-2643
http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO http://photoarchive.ap.org/ DATASOURCE: EntreMed, Inc.
CONTACT: Ginny Dunn, Associate Director, Corporate Communications & Investor Relations, EntreMed, Inc., +1-240-864-2643 Web site: http://www.entremed.com/
|